Incretin-based therapies have been in use for nearly a decade now, as add-on agents to conventional therapy and as initial treatment for some patients. Here, a quick brush-up on GLP-1 agonists and DPP-4 inhibitors.
The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?
Achieving sustained reductions of hyperlipidemia and blood pressure in a patient with diabetes is not impossible, but it's a challenge. A new study comparing two health systems shows which factors increase the odds of success.
Bariatric surgery nearly cures type 2 diabetes—at least that’s what results of a new study seem to imply. The study, presented at the recent ACC meeting and published in NEJM, found that 42% of patients randomly assigned to the stomach-reducing surgery quickly reached HbA1C targets and remained controlled at 1-year follow-up.